Aspira Women's Health Inc. - Common Stock (AWH)

Frequently Asked Questions About Aspira Women's Health Inc. - Common Stock (AWH)

Are there any ongoing clinical trials for Aspira Women's Health Inc.'s products?

Yes, Aspira Women's Health Inc. frequently conducts clinical trials to validate its diagnostic products and to explore novel applications of its tests. These trials help gather critical data, support regulatory submissions, and enable continual improvement of their testing capabilities.

Does Aspira Women's Health Inc. offer any other products?

In addition to the Ova1 test, Aspira Women's Health Inc. is in the process of developing and validating additional diagnostic tests aimed at improving women's health. These include tests that assess the risk of other gynecological diseases, expanding the company's diagnostic portfolio.

How can patients access Aspira Women's Health Inc.'s tests?

Patients can access Aspira Women's Health Inc.'s tests through their healthcare providers. Clinicians order the tests based on individual patient needs and circumstances. The test results, once analyzed, are communicated back to the patient through their healthcare provider.

How does Aspira Women's Health Inc. contribute to women's healthcare education?

Aspira Women's Health Inc. contributes to women's healthcare education by providing resources and information about women's health issues, diagnostics, and disease prevention. The company actively engages with healthcare providers and patients to raise awareness about the importance of early detection and the availability of its testing solutions.

How does Aspira Women's Health Inc. ensure the accuracy of its tests?

Aspira Women's Health Inc. ensures the accuracy of its tests through rigorous clinical validation studies, adherence to regulatory standards, and continuous monitoring of test performance. The company employs a team of experts in clinical research and data analysis to uphold high-quality standards.

How does Aspira Women's Health Inc. plan to grow its business?

Aspira Women's Health Inc. plans to grow its business through a combination of expanding its product offerings, increasing market penetration of its existing tests, pursuing partnerships and collaborations with healthcare institutions, and investing in research and development to innovate new diagnostic tests.

Is Aspira Women's Health Inc. a public company?

Yes, Aspira Women's Health Inc. is a publicly traded company listed on the Nasdaq under the ticker symbol AWH. The company went public to raise funds for its research and development initiatives and to expand its market presence.

Is Aspira Women's Health Inc. involved in any partnerships?

Yes, Aspira Women's Health Inc. actively engages in partnerships with academic institutions, healthcare organizations, and other companies to enhance its research capabilities and broaden the reach of its diagnostic solutions. Collaborations are essential for driving innovation and improving healthcare outcomes for women.

What are Aspira Women's Health Inc.'s research initiatives?

Aspira Women's Health Inc. conducts various research initiatives focused on the discovery and validation of biomarkers related to women's health. These initiatives are aimed at developing new diagnostic tests and enhancing the precision of existing tests, ensuring that they provide clinically relevant information.

What are the future prospects for Aspira Women's Health Inc.?

The future prospects for Aspira Women's Health Inc. appear promising as the demand for women's health diagnostics continues to grow. With ongoing research and development, potential product expansions, and strategic partnerships, the company is positioned to strengthen its impact in the healthcare sector and provide innovative solutions for women's health issues.

What challenges does Aspira Women's Health Inc. face?

Like many companies in the healthcare and diagnostics sectors, Aspira Women's Health Inc. faces challenges such as regulatory hurdles, reimbursement issues, market competition, and the need for ongoing scientific validation of its tests. Overcoming these challenges is critical for sustaining growth and achieving broader adoption of its products.

What does Aspira Women's Health Inc. do?

Aspira Women's Health Inc. is a diagnostic company focused on developing novel solutions to improve the detection of women's health conditions, particularly related to reproductive health and gynecological cancers. The company aims to empower women and healthcare providers with innovative, accurate, and non-invasive diagnostic tests.

What is the importance of early detection in women's health?

Early detection in women's health, particularly for conditions like ovarian cancer, is paramount as it significantly enhances treatment outcomes and survival rates. Diagnosing diseases at an earlier stage allows for more effective interventions, ultimately improving overall quality of life for patients.

What is the primary product of Aspira Women's Health Inc.?

Aspira Women's Health Inc. primarily offers the Ova1 test, which is designed to assess the likelihood of ovarian cancer in women with adnexal masses. This test utilizes a combination of biomarkers to provide a risk assessment, helping clinicians make informed decisions about further testing and treatment.

What is the role of biomarkers in Aspira's testing?

Biomarkers play a crucial role in Aspira Women's Health Inc.'s testing by serving as biological indicators of disease processes. In the context of the Ova1 test, a specific panel of biomarkers is utilized to assess ovarian cancer risk, enabling more informed clinical decision-making.

What is the significance of the Ova1 test?

The Ova1 test is significant because it provides a more accurate assessment of ovarian cancer risk in women presenting with ovarian masses. Its introduction marks an advancement in the early detection of a disease that can be challenging to diagnose, ultimately aiding in timely and appropriate medical intervention.

What type of testing does Aspira Women's Health Inc. provide?

Aspira Women's Health Inc. focuses on biomarker testing for women's health, particularly for early detection of ovarian cancer and other gynecological conditions. Their flagship product, Ova1, assesses the risk of cancer in women with ovarian masses through a series of blood tests.

When was Aspira Women's Health Inc. founded?

Aspira Women's Health Inc. was founded in 2009, with the objective of developing innovative products and technologies that improve women's health outcomes. Since its inception, the company has focused on enhancing diagnostic capabilities for gynecological conditions.

Where is Aspira Women's Health Inc. headquartered?

The headquarters of Aspira Women's Health Inc. is located in Austin, Texas. This strategic location allows the company to collaborate with medical professionals and institutions while being at the forefront of advancements in women's health diagnostics.

Who are the target customers for Aspira Women's Health Inc.?

Aspira Women's Health Inc.'s target customers include healthcare providers such as gynecologists, oncologists, and primary care physicians who are responsible for diagnosing and treating women's health issues. Additionally, the company aims to reach hospitals and labs that perform diagnostic testing.

What is the current price of Aspira Women's Health Inc. - Common Stock?

The current price of Aspira Women's Health Inc. - Common Stock is 0.1002

When was Aspira Women's Health Inc. - Common Stock last traded?

The last trade of Aspira Women's Health Inc. - Common Stock was at 4:00 pm EDT on April 3rd, 2025

What is the market capitalization of Aspira Women's Health Inc. - Common Stock?

The market capitalization of Aspira Women's Health Inc. - Common Stock is 2.98M

How many shares of Aspira Women's Health Inc. - Common Stock are outstanding?

Aspira Women's Health Inc. - Common Stock has 29.76M shares outstanding.